Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The Wall Street Journal reported that the SEC had launched a probe into claims that Cassava Sciences Inc (NASDAQ:SAVA) manipulated data key to its case for its experimental Alzheimer’s drug simufilam.
- The report comes just two days after Cassava, in an SEC filing, revealed that “certain government agencies” had asked the Company for documentation.
- It wasn’t clear which agencies were inquiring or what information they sought, and Cassava did say that the requests weren’t accusations of wrongdoing.
- Now, with the SEC’s involvement, regulators will take a close look at claims dating to August that Cassava manipulated Western blot images used to back its drug’s case.
- In November, the Journal of Neuroscience, which published one of the simufilam papers in question, said an internal review found no instances of data manipulation. However, the journal did find a duplicated image and issued a correction.
- Price Action: SAVA shares are down 22.4% at $47.85 during the market session on the last check Wednesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!